Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 328

1.
2.
3.

Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs.

Rawal RK, Murugesan V, Katti SB.

Curr Med Chem. 2012;19(31):5364-80. Review.

PMID:
22998569
4.

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C.

J Virol. 2001 Jun;75(11):4999-5008.

5.
6.

Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

Balzarini J.

Curr Top Med Chem. 2004;4(9):921-44. Review. Erratum in: Curr Top Med Chem. 2004;4(16):1825.

PMID:
15134549
7.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.

De Clercq E.

Chem Biodivers. 2004 Jan;1(1):44-64. Review.

PMID:
17191775
8.

Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.

Campiani G, Ramunno A, Maga G, Nacci V, Fattorusso C, Catalanotti B, Morelli E, Novellino E.

Curr Pharm Des. 2002;8(8):615-57. Review.

PMID:
11945162
9.

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.

Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V.

J Med Virol. 2001 Nov;65(3):445-8.

PMID:
11596076
10.

International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.

Deeks SG.

J Acquir Immune Defic Syndr. 2001 Mar 1;26 Suppl 1:S25-33. Review.

PMID:
11264999
11.

[Non-nucleoside reverse transcriptase inhibitors].

Joly V, Yeni P.

Ann Med Interne (Paris). 2000 Jun;151(4):260-7. Review. French.

PMID:
10922953
12.

NNRTIs: a neglected class.

Cadman J.

GMHC Treat Issues. 1998 Sep;12(9):6-10.

PMID:
11365807
13.

New developments in anti-HIV chemotherapy.

De Clercq E.

Curr Med Chem. 2001 Nov;8(13):1543-72. Review.

PMID:
11562282
14.

Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.

Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme AM.

AIDS. 1999 Aug 20;13(12):1477-83.

PMID:
10465070
15.

Delavirdine: a review of its use in HIV infection.

Scott LJ, Perry CM.

Drugs. 2000 Dec;60(6):1411-44. Review.

PMID:
11152019
16.
17.

In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.

Gianotti N, Boeri E, Maillard M, Serra G, Ratti D, Gallotta G, Vacchini D, Tremolada Y, Castagna A.

New Microbiol. 2004 Apr;27(2 Suppl 1):111-7.

PMID:
15646073
18.

Clinical uses of non-nucleoside reverse transcriptase inhibitors.

Harris M, Montaner JS.

Rev Med Virol. 2000 Jul-Aug;10(4):217-29. Review.

PMID:
10891870
19.

Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.

Tozzi V, Zaccarelli M, Narciso P, Trotta MP, Ceccherini-Silberstein F, De Longis P, D'Offizi G, Forbici F, D'Arrigo R, Boumis E, Bellagamba R, Bonfigli S, Carvelli C, Antinori A, Perno CF.

J Infect Dis. 2004 May 1;189(9):1688-95. Epub 2004 Apr 13.

PMID:
15116307
20.

In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.

Kollmann C, Tremblay C, Giguel F, Chou TC, Hirsch MS.

Antivir Ther. 2001 Jun;6(2):143-4. No abstract available.

PMID:
11491419

Supplemental Content

Support Center